Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.
Gastrointestinal stromal tumors (GIST) are characterized by activating mutations of KIT or platelet-derived growth factor receptor A (PDGFRA), and treatment with the tyrosine kinase inhibitor imatinib yields responses in the majority of patients. However, most patients develop secondary resistance, which is associated with a dismal prognosis. Histone deacetylase inhibitors (HDACI) have been shown to enhance imatinib activity in imatinib-resistant chronic myelogenous leukemia. Against this background, we explored whether HDACI might provide an alternative therapeutic strategy to KIT/PDGFRA kinase inhibitors in GIST. Inhibition of cell proliferation by HDACI was seen in KIT-positive but not in KIT-negative GIST cell lines, suggesting that HDACI activity is mainly conferred by targeting oncogenic KIT. KIT activity, expression, and activation of downstream pathways were strongly inhibited by several HDACI (SAHA, LBH589, VPA, trichostatin A, and NaButyrate). SAHA and LBH589 induced apoptosis in KIT-positive GIST, and strong synergism with imatinib was observed at low concentrations of SAHA and LBH589. Mechanistically, treatment with HDACI reduced KIT mRNA transcript levels and led to strong acetylation of HSP90, interfering with its activity as KIT chaperone. These results provide preclinical evidence for a disease-specific effect of HDACI in KIT-positive GIST, which could translate into therapeutic activity.
Mühlenberg
Thomas
T
Sarcoma Center, West German Cancer Center, University of Essen, Medical School, Essen, Germany.
Zhang
Yixiang
Y
Wagner
Andrew J
AJ
Grabellus
Florian
F
Bradner
James
J
Taeger
Georg
G
Lang
Hauke
H
Taguchi
Takahiro
T
Schuler
Martin
M
Fletcher
Jonathan A
JA
Bauer
Sebastian
S
D000107:Acetylation; D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D018841:HSP90 Heat-Shock Proteins / Q000378:metabolism*; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D000077337:Vorinostat
D004791:Enzyme Inhibitors; D018841:HSP90 Heat-Shock Proteins; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat; D019009:Proto-Oncogene Proteins c-kit; D006655:Histone Deacetylases
Cancer Res. 2003 May 1;63(9):2118-26
12727828
Oncogene. 2001 Aug 16;20(36):5054-8
11526490
J Clin Oncol. 2003 Dec 1;21(23):4342-9
14645423
Nat Rev Cancer. 2001 Dec;1(3):194-202
11902574
Stem Cells. 2004;22(6):1070-84
15536197
Oncogene. 2007 Aug 13;26(37):5420-32
17694083
J Clin Oncol. 2006 Oct 10;24(29):4764-74
16954519
Cancer Sci. 2005 Feb;96(2):116-9
15723656
Oncogene. 2007 Nov 29;26(54):7560-8
17546049
J Biol Chem. 1998 Dec 4;273(49):32608-13
9829999
Clin Cancer Res. 2006 Apr 15;12(8):2622-7
16638875
J Invest Dermatol. 2005 Nov;125(5):1045-52
16297208
Mol Cancer Ther. 2006 Sep;5(9):2203-10
16985053
Nat Rev Drug Discov. 2002 Apr;1(4):287-99
12120280
Lancet Oncol. 2005 Apr;6(4):249-51
15811621
Anticancer Res. 2006 Mar-Apr;26(2A):1247-52
16619531
Nat Rev Drug Discov. 2007 Jan;6(1):21-2
17269160
Leukemia. 2005 Sep;19(9):1579-89
16015388
Science. 1998 Jan 23;279(5350):577-80
9438854
J Biol Chem. 2005 Jul 22;280(29):26729-34
15937340
Oncogene. 2008 Sep 18;27(42):5624-34
18521081
Oncogene. 2004 May 13;23(22):3999-4006
15007386
Cancer Cell. 2005 Feb;7(2):129-41
15710326
Mol Cell. 2005 May 27;18(5):601-7
15916966
Cancer Res. 2001 Nov 15;61(22):8118-21
11719439
Lancet. 2006 Oct 14;368(9544):1329-38
17046465
Clin Cancer Res. 2006 Mar 15;12(6):1743-9
16551858
Science. 2003 Jan 31;299(5607):708-10
12522257
Mol Cell. 2007 Jan 12;25(1):151-9
17218278
J Pathol. 2001 Apr;193(4):505-10
11276010
Pharmacology. 2006;77(1):11-6
16534250
J Clin Oncol. 2008 Feb 1;26(4):620-5
18235121
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
10954755
Cancer Res. 2003 Aug 15;63(16):5126-35
12941844
Adv Cancer Res. 2004;91:137-68
15327890
J Biol Chem. 2005 Oct 7;280(40):33792-9
16087666
Blood. 2003 Apr 15;101(8):3236-9
12446442
J Biomol Screen. 2002 Jun;7(3):223-31
12097185
Ann Surg. 2000 Jan;231(1):51-8
10636102
J Immunol Methods. 1993 Mar 15;160(1):81-8
7680699
Cancer Res. 2006 Sep 15;66(18):9153-61
16982758
Nature. 2007 May 24;447(7143):407-12
17522673
APMIS. 2005 Apr;113(4):264-8
15865607